Sign in
Active, not recruitingNo phase

Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

Key facts

Who runs it
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
50 people, planned
Started
11 Nov 2023
Expected to end
31 Dec 2040
Type of study
Interventional
Treatments tested
  • Adjuvant Hypofractionation Radiotherapy
Record updated
16 June 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Thymoma and Thymic carcinoma confirmed by histology or cytology
  • R0 resection (complete resection)
  • stage II and III thymic carcinoma,stage III thymoma,stage IIB B2/B3 thymomas
  • Karnofsky performance status(KPS) 80, 90 or 100
  • Having sufficient Pulmonary function, renal function and liver function. Neutrophile granulocyte count>1.5×109 /L, platelet count>80×109 /L, hemoglobin ≥10g/dL

Who cannot take part

  • Prior thoracic radiotherapy
  • Uncontrolled Comorbidities
  • Pregnant or nursing mother
  • Pneumonia

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficiency and toxicity of adjuvant hypofractionation radiotherapy for thymic epithelial tumours after complete resection.

The group in the trial

  • Adjuvant Hypofractionation RadiotherapyTreatment being tested

    Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection-Single Center Phase II Single Arm Clinical Trial
Record updated
16 June 2026